Two ACR 2025 analyses link SGLT2 inhibitors to fewer RA flares and a lower risk for osteoarthritis than GLP-1 receptor ...

"Imugene announces Phase Ib azer-cel efficacy data" was originally created and published by Clinical Trials Arena, a ...

Innovent's Pecondle, a recombinant anti-interleukin-23p19 subunit, receives China NMPA approval to treat moderate-to-severe plaque psoriasis: San Francisco Monday, December 1, 202 ...

Using human iPSC-derived kidney organoids, researchers showed that NPHP1 deficiency triggers abnormal Hippo signaling that ...

A simple blood test analysed by artificial intelligence could revolutionise early detection of primary vitreoretinal lymphoma ...

Imugene Ltd (ASX:IMU, OTC:IUGNF) has reported another uplift in efficacy data from its Phase 1b trial of azer-cel, its allogeneic, off-the-shelf CD19 ...

Sun Pharma introduces Ilumya in India for treatment of moderate-to-severe plaque psoriasis: Our Bureau, Mumbai Tuesday, December 2, 2025, 14:45 Hrs [IST] Sun Pharma has announced ...

The use of IL-1 alpha and beta inhibition with ARCALYST has increasingly become the preferred treatment for recurrent ...

Well, that's a very important question and distinction and I would have our CMO, Sam, take a crack at it. Samuel Saks: Yes. I ...

Different subsets of γδ T cells display differential expression of immune checkpoint receptors (ICRs) and have distinct ...

Recent research published in the Journal of Psychiatric Research indicates that specific clusters of depressive symptoms are ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...